Articles

1. Sparsentan in immunoglobulin A nephropathy: a profile of its use

   • Young-A Heo
   • Connie Kang

   Adis Drug Q&A 29 March 2024 Pages: 101 - 108

2. What is the role of pioglitazone for patients with type 2 diabetes in value-based care settings?

   • Andrea Bush
   • Tina Benny
   • Matthew Seamon

   Current Opinion 28 March 2024 Pages: 131 - 136

   

3. Treating paediatric Crohn’s disease is challenging but new treatments hold promise

   • Tina Nie

   Disease Management 28 March 2024 Pages: 121 - 126

4. Correction to: Efanesoctocog alfa in hemophilia A: a profile of its use

   • Simon Fung
   • Hannah A. Blair

   Correction Open access 21 March 2024 Pages: 138 - 138

5. Correction to: Nadofaragene firadenovec in high-risk Bacillus Calmette Guérin unresponsive non-muscle invasive bladder cancer: a profile of its use

   • Tina Nie

   Correction Open access 21 March 2024 Pages: 137 - 137

6. Be aware of the risks of nephrotoxicity when prescribing amoxicillin and third-generation cephalosporins

   • Amy Zhuang-Yan

   Drug Reactions and Interactions 21 March 2024 Pages: 127 - 130

7. Treat bipolar depression with atypical antipsychotics and mood stabilisers; new therapies require further study

   • Simon Fung

   Practical Issues and Updates 11 March 2024 Pages: 109 - 114

8. Get on top of gout with a fresh look at treatment options

   • Caroline Fenton
   • Connie Kang

   Practical Issues and Updates 04 April 2024 Pages: 115 - 120

9. Evaluation of diclofenac utilization patterns before and after digital risk minimization intervention in outpatient settings in Montenegro

   • Maja Stankovic
   • Nemanja Turkovic
   • Nemanja Rancic

   Original Research Article 24 February 2024 Pages: 90 - 100

   

10. Multisite primary care led amoxicillin challenge pathway to safely remove penicillin allergy label

    • David C. Mari
    • Kelley M. Henson
    • Taylor A. Banks

    Therapy in Practice 10 March 2024 Pages: 83 - 89

    

11. Administer antidepressants during pregnancy on a case-by-case basis

    • Yvette N. Lamb
    • Simon Fung

    Practical Issues and Updates 10 March 2024 Pages: 78 - 82

12. Metformin reduces the complications of gestational diabetes mellitus but its long-term effects on offspring require further study

    • Simon Fung

    Practical Issues and Updates 10 March 2024 Pages: 72 - 77

13. Buprenorphine extended-release injection (Brixadi^®) in the management of opioid use disorder: a profile of its use in the USA

    • Hannah A. Blair

    Adis Drug Q&A 15 March 2024 Pages: 61 - 71

14. Mirvetuximab soravtansine in folate receptor alpha-positive, platinum-resistant ovarian cancers: a profile of its use

    • Simon Fung
    • Yahiya Y. Syed

    Adis Drug Q&A 10 March 2024 Pages: 53 - 60

    

15. Pirtobrutinib in relapsed or refractory mantle cell lymphoma: a profile of its use

    • Young-A Heo

    Adis Drug Q&A 27 January 2024 Pages: 45 - 52

16. Preferably pre-empt pathological scars, or pick from a plethora of therapies

    • Caroline Fenton
    • Yvette N. Lamb

    Practical Issues and Updates 08 January 2024 Pages: 22 - 26

17. Correction to: Tezepelumab in severe asthma: a profile of its use

    • Yahiya Y. Syed

    Correction Open access 05 January 2024 Pages: 43 - 43

18. Platelet-rich plasma therapy for chronic cutaneous wounds stratified by etiology: a systematic review of randomized clinical trials

    • Verónica Salgado-Pacheco
    • Montserrat Serra-Mas
    • Marta Otero-Viñas

    Systematic Review Open access 28 February 2024 Pages: 31 - 42

    

19. Expand the treatment horizon of premenstrual dysphoric disorder with targeted therapeutic approaches

    • Young-A Heo

    Practical Issues and Updates 24 February 2024 Pages: 27 - 30

20. Treat borderline personality disorder with psychotherapy and concomitant psychiatric disorders with adjuvant pharmacotherapy

    • Esther S. Kim
    • Yvette N. Lamb

    Disease Management 24 February 2024 Pages: 17 - 21

21. Efanesoctocog alfa in hemophilia A: a profile of its use

    • Simon Fung
    • Hannah A. Blair

    Adis Drug Q&A Open access 24 February 2024 Pages: 9 - 16

    

22. Nadofaragene firadenovec in high-risk Bacillus Calmette Guérin unresponsive non-muscle invasive bladder cancer: a profile of its use

    • Tina Nie

    Adis Drug Q&A Open access 24 February 2024 Pages: 1 - 8

23. Nirsevimab in the prevention of respiratory syncytial virus lower respiratory tract disease: a profile of its use

    • Matt Shirley

    Adis Drug Q&A 22 December 2023 Pages: 413 - 420

24. The PHASTER Study: Economic and Organizational Impact of Subcutaneous (SC) Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Treatment of HER2+ Breast Cancer Patients

    • Elisabetta Munzone
    • Alessandra Fabi
    • Michelino De Laurentiis

    Original Research Article Open access 21 December 2023 Pages: 432 - 446

    

25. Acknowledgement to Referees

    Acknowledgement to Referees 20 December 2023 Pages: 448 - 451

26. Understand the benefits and risks of intravenous methadone for perioperative and chronic cancer pain management

    • Tina Nie

    Practical Issues and Updates 13 December 2023 Pages: 426 - 431

27. Tezepelumab in severe asthma: a profile of its use

    • Yahiya Y. Syed

    Adis Drug Q&A Open access 07 December 2023 Pages: 393 - 403

28. Spesolimab in generalised pustular psoriasis flares: a profile of its use

    • Tina Nie

    Adis Drug Q&A 02 December 2023 Pages: 404 - 412

29. Correction to: RBX2660 (REBYOTA^®) in preventing recurrence of Clostridioides difficile infection: a profile of its use in the USA

    • Hannah A. Blair

    Correction Open access 24 November 2023 Pages: 447 - 447

30. Manage vitiligo with a personalised approach: consider old and new treatments

    • Nicole L. France

    Disease Management 24 November 2023 Pages: 421 - 425

    

31. The role of belzutifan, an inhibitor of hypoxia-inducible factor, for renal cell carcinoma in adults with Von Hippel–Lindau disease: a review

    • Anne M. Schwartz
    • Waddih Fakhre
    • Alan D. Kaye

    Review Article 21 November 2023 Pages: 388 - 392

32. Ublituximab in relapsing forms of multiple sclerosis: a profile of its use

    • Hannah A. Blair

    Adis Drug Q&A 06 November 2023 Pages: 365 - 372

33. Deucravacitinib in plaque psoriasis: a profile of its use

    • Arnold Lee

    Adis Drug Q&A 01 November 2023 Pages: 357 - 364

    

34. Towards intra-articular therapies for more than just symptom management in osteoarthritis

    • Simon Fung

    Practical Issues and Updates 09 October 2023 Pages: 382 - 387

35. Manage idiopathic hypersomnia with a combination of non-pharmacological and pharmacological treatments

    • Arnold Lee

    Practical Issues and Updates 03 October 2023 Pages: 378 - 381

36. First reports of adverse drug reactions

    First reports of adverse drug reactions 29 September 2023 Pages: 353 - 353

37. Go with your gut: targeting the microbiome for treatment of irritable bowel syndrome

    • Simon Fung

    Disease Management 23 September 2023 Pages: 373 - 377

38. RBX2660 (REBYOTA^®) in preventing recurrence of Clostridioides difficile infection: a profile of its use in the USA

    • Hannah A. Blair

    Adis Drug Q&A Open access 23 September 2023 Pages: 331 - 338

39. Prescribe colchicine with care and be aware of colchicine drug interactions

    • Amy Zhuang-Yan
    • Connie Kang

    Drug Reactions and Interactions 22 September 2023 Pages: 348 - 352

40. Addressing the opioid epidemic in Pakistan: urgent need for opioid stewardship and comprehensive solutions

    • Adeel Siddiqui
    • Sunil Shrestha
    • Omar Akhlaq Bhutta

    Commentary 05 September 2023 Pages: 354 - 356

41. Nails blue? Don’t be sad, the cause may be discoverable

    • Arnold Lee

    Drug Reactions and Interactions 30 August 2023 Pages: 344 - 347

    

42. Treat functional constipation in children with conventional options first and consider alternatives if needed

    • Tina Nie

    Practical Issues and Updates 28 August 2023 Pages: 339 - 343

43. Linzagolix in moderate to severe symptoms of uterine fibroids: a profile of its use

    • Simon Fung
    • Hannah A. Blair

    Adis Drug Q&A 22 August 2023 Pages: 309 - 316

    

44. Manage truncal acne and scarring the same as for facial acne, but more trunk-specific therapies are warranted

    • Connie Kang

    Disease Management 18 August 2023 Pages: 324 - 329

    

45. First reports of adverse drug reactions

    Drug Reactions and Interactions 31 July 2023 Pages: 330 - 330

46. Adis Summary of Research: Safety, Effectiveness, and Immunogenicity 6 Months After BNT162B2 mRNA Vaccine in Frail Nursing Home Residents

    • Julia Paik
    • Zaina T. Al-Salama

    Adis Summary of Research 29 July 2023 Pages: 317 - 318

    

47. Consider comorbidities, concomitant medications and organ function when treating chronic urticaria in older adults

    • Tina Nie

    Disease Management 27 July 2023 Pages: 319 - 323

    

48. Tapinarof cream 1% in plaque psoriasis: a profile of its use

    • Matt Shirley

    Adis Drug Q&A 27 July 2023 Pages: 303 - 308

49. Screen for drug-induced gambling disorder in vulnerable patients receiving dopaminergic drugs

    • Simon Fung

    Practical Issues and Updates 21 July 2023 Pages: 297 - 301

50. Manage early morning ADHD symptoms and functional impairment with treatments that are effective from awakening

    • Tina Nie

    Disease Management 21 July 2023 Pages: 287 - 291